

Sample Letter
ZYNRELEF (bupivacaine and meloxicam)
Separate Payment Request (HCPCS Code C9088)

[PRACTICE LETTERHEAD]

[Date]

[Dr/Mr/Ms] [Medical Director Name]
[Name of Health Insurance Company]
[Insurer Address]
[City], [State] [Zip Code]

Dear [Dr/Mr/Ms] [Surname of Medical Director]:

At [NAME] our mission is to reduce unnecessary opioid exposure by prescribing non-opioid pain management options. To support this initiative, we urge [Payer] to align our commercial contract with Medicare's Non-Opioid Policy for Pain Relief and ensure separate payment for ZYNRELEF (HCPCS Code C9088) outside of the surgical supply package in the [HOPD or ASC].

Wholesale Acquisition Cost (WAC)

- ZYNRELEF 200mg VAN: [\$\$]
- ZYNRELEF 400mg VAN: [\$\$]

Legislative Background

Starting January 1, 2025, the Consolidated Appropriations Act, 2023 (§4135) (P.L. 117-328) mandates separate payment for qualifying non-opioid treatments in the HOPD and ASC settings of care. Now formally recognized as the Non-Opioid Policy for Pain Relief, this initiative aims to remove financial barriers that might otherwise discourage the use of non-opioid alternatives.

For full details, refer to the 2025 OPPS final rule: [Search the 2025 OPPS final rule for Non-Opioid Policy for Pain Relief](#)

The Key Inclusion Criteria

To qualify for separate payment under this policy, the non-opioid treatment must have:

- A label indication approved by the Food and Drug Administration to reduce postoperative pain, or produce postsurgical or regional analgesia, without acting upon the body's opioid receptors.

- Demonstrated the ability to replace, reduce, or avoid intraoperative or postoperative opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.

Addressing Financial Barriers

Under [Payer]'s current commercial payment mechanisms, financial barriers persist in accessing ZYNRELEF. We urge [Payer] to:

- Eliminate these barriers and enable separate reimbursement for ZYNRELEF (HCPCS Code C9088).
- Align with Medicare's Non-Opioid Policy for Pain Relief, ensuring providers have unrestricted access to opioid-free alternatives for your members.

By taking these steps, [Payer] can help drive safer pain management practices while reducing reliance on opioids. We appreciate your attention to this critical matter and look forward to further discussions.

Sincerely,

[Name]

[Title]

[Phone Number]

Please see full Prescribing Information, including Boxed Warning and updated Warnings and Precautions for serious skin reactions caused by nonsteroidal anti-inflammatory drugs (NSAIDs).